CTAG1B and ovarian cancer: For instance, treatment with the CTLA-4 checkpoint inhibitor ipilimumab has been reported to induce specific NY-ESO-1 humoral and cellular immune responses in patients with ovarian cancer, prostate cancer, and metastatic melanoma (100, 125–135).